Literature DB >> 21790560

Definition and natural history of Lennox-Gastaut syndrome.

Peter R Camfield1.   

Abstract

Lennox-Gastaut syndrome (LGS) is a rare epileptic encephalopathy with a peak age of onset of 3-5 years of age. Reported prevalence rates for LGS vary widely from 1-10% of all childhood epilepsies. Incidence rates are much lower. LGS is characterized by intractable, multiple, generalized seizure types and an interictal electroencephalogram showing bursts of slow spike-and-wave, paroxysmal bursts of generalized polyspikes, and a slow background. All patients have tonic seizures during sleep that may be subtle, and nearly all have treatment-resistant, lifelong epilepsy. Cognitive stagnation and behavioral problems are seen in almost all patients and lead to a life of dependency. The differential diagnosis includes other symptomatic generalized epilepsies and pseudo-Lennox syndrome. Misdiagnosis is common. Children and adults with LGS have an enormous impact on their families, and efforts to improve the quality of life for these patients are complex. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2011        PMID: 21790560     DOI: 10.1111/j.1528-1167.2011.03177.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  40 in total

1.  Elevated serotonergic signaling amplifies synaptic noise and facilitates the emergence of epileptiform network oscillations.

Authors:  Pavel A Puzerey; Michael J Decker; Roberto F Galán
Journal:  J Neurophysiol       Date:  2014-08-13       Impact factor: 2.714

2.  Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Simona Lattanzi; Francesco Brigo; Claudia Cagnetti; Eugen Trinka; Mauro Silvestrini
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

3.  A 7-Year-Old Boy with Intractable Seizures and Snoring.

Authors:  Casandra Arevalo; Lourdes M DelRosso; Ilya Khaytin; Lawrence Brown
Journal:  J Clin Sleep Med       Date:  2016-06-15       Impact factor: 4.062

Review 4.  Lennox-Gastaut syndrome: a comprehensive review.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

Review 5.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

6.  Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.

Authors:  Anna Jeong; Michael Wong
Journal:  J Child Neurol       Date:  2017-03-16       Impact factor: 1.987

Review 7.  Single-Gene Determinants of Epilepsy Comorbidity.

Authors:  Jeffrey L Noebels
Journal:  Cold Spring Harb Perspect Med       Date:  2015-11-02       Impact factor: 6.915

Review 8.  Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Ben Wijnen; Nigel Armstrong; Bram Ramaekers; Willem Witlox; Marie Westwood; Debra Fayter; Steve Ryder; Titas Buksnys; Gill Worthy; Kate Misso; Sabine Grimm; Jos Kleijnen; Manuela Joore
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981

9.  Abnormal cell-intrinsic and network excitability in the neocortex of serotonin-deficient Pet-1 knockout mice.

Authors:  Pavel A Puzerey; Nathan X Kodama; Roberto F Galán
Journal:  J Neurophysiol       Date:  2015-11-25       Impact factor: 2.714

10.  Efficacy and safety of rufinamide in pediatric epilepsy.

Authors:  David T Hsieh; Elizabeth A Thiele
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.